Atika Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Atika Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.9M	Sell	440,000 -37,000	-8%	-$1.23M	0.98%	29
2026 Q1	$14.4M	Sell	477,000 -240,000	-33%	-$7.72M	1.8%	16
2025 Q4	$22.4M	Buy	717,000 +493,000	+220%	+$12.1M	2.36%	7
2025 Q3	$4.52M	Buy	+224,000	New	+$3.93M	0.36%	63
2025 Q2	–	Sell	-436,900	Closed	-$6.72M	–	78
2025 Q1	$6.72M	Buy	+436,900	New	+$7.8M	0.94%	37
2015 Q2	–	Sell	-38,000	Closed	-$2.37M	–	75
2015 Q1	$2.37M	Buy	+38,000	New	+$2.21M	1.58%	29

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Atika Capital Management's TEVA Position: Q2 2026 in Review

Atika Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 7.8% in Q2 2026, selling an estimated $1.23M and leaving 440,000 shares worth $14.9M. The position accounts for 0.98% of the portfolio, ranked #29.

Atika Capital Management first reported a position in TEVA in Q1 2015 and has held it in 6 quarters since. The position peaked at $22.4M in Q4 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Atika Capital Management held 440,000 shares of Teva Pharmaceuticals worth $14.9M as of Q2 2026.
Atika Capital Management sold 37,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.23M.
Teva Pharmaceuticals made up 0.98% of Atika Capital Management's portfolio in Q2 2026, its #29 holding.
Atika Capital Management first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 6 quarters since.
Atika Capital Management's Teva Pharmaceuticals position peaked at $22.4M in Q4 2025.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.